- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06004661
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
An Open-label Dosimetry, Biodistribution, Tolerability and Safety Study of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Moderately and Severely Impaired and With Normal Renal Function.
Study Overview
Status
Intervention / Treatment
Detailed Description
This open-label, non-randomized, multicenter, single arm phase II study in mCRPC participants aims to better characterize the safety and tolerability of AAA617 in participants with moderate and severe renal impairment compared with normal renal function. Since both severe and moderate renal impairment have very low incidence within mCRPC participant population compared to participants with normal renal function, the enrollment will occur in parallel for the 3 cohorts; participants will be stratified in one of the three cohorts (A:normal, B: moderate or C: severe) based on their eGFR at screening.
All participants will undergo a 68Ga-PSMA-11 PET/CT scan at screening to confirm PSMA positivity.
Participants will receive a dose of 7.4 GBq (±10%) of AAA617 once every 6 weeks for a planned 6 cycles for cohorts A and B and for 3 cycles (and 3 additional cycles) for cohort C.
After treatment period, participants will be asked to join a long term follow up (LTFU) study to monitor their safety up to 10 years after the 1st dose of AAA617. In case of the LTFU study is not available at the time of end of treatment period (safety follow-up visit), participants will continue in Long Term Follow-up period in this study for up to one year until they can roll over into the separate LTFU study.
The primary outcome will be to determine the effect of radiation absorption in kidney and other organs at risk as well as the concentration in blood and radioactivity in urine in PSMA- positive mCRPC participants with moderate and severe renal impairment. In addition, the study will assess the relationship between drug concentrations and QTcF.
20 participants with 6 countries are expected to be included with at least 6 evaluable participantts per cohort.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: 1-888-669-6682
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
- Email: novartis.email@novartis.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- 68Ga-PSMA-11 Positron emission tomography (PET)/CT scan positive, and eligible as determined by the sponsor's central reader.
- A castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L).
Documented progressive mCRPC will be based on at least 1 of the following criteria:
- Serum/plasma Prostate-Specific Antigen (PSA) progression defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week prior. The minimal start value is 2.0 ng/mL
- Soft-tissue progression defined as an increase >= 20% in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or more new lesions.
- Progression of bone disease: evaluable disease or new bone lesions(s) by bone scan (2+2 PCWG3 criteria)
- Documented stable renal disease without evidence of renal progressive disease (stable renal disease is defined as no significant change, such as a stable eGFR, within 4 weeks prior to study entry)
Kidney function based on eGFR by Modification of Diet in Renal Disease (MDRD) equation:
- Normal renal function: participants with eGFR >= 90 mL/min
- Moderate renal impairment: participants with eGFR >= 30 to =< 59 mL/min
- Severe renal impairment: participants with eGFR >= 15 to =< 29 mL/min
Key Exclusion Criteria:
- Previous treatment with PSMA-targeted radioligand therapy.
- Previous treatment with any of the following within 6 months of enrollment confirmation: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223 or hemi-body irradiation.
- Use of agents known to prolong the QT interval from start of screening to end of Cycle 1, unless they can be permanently discontinued for the duration of study.
- Current severe urinary incontinence, hydronephrosis, severe voiding dysfunction, any level of urinary obstruction requiring indwelling/condom catheters. Participants with postrenal impairment, like obstructions, retroperitoneal fibrosis (eg after prostectomy) must be excluded or first resolved to ≤ Grade 1.
History or current diagnosis of ECG abnormalities indicating significant risk of safety for participants participating in the study such as:
- Concomitant clinically significant cardiac arrhythmias, e.g. sustained ventricular tachycardia, and clinically significant second- or third-degree AV block without a pacemaker.
- History of familial long QT syndrome or known family history of Torsades de Pointe.
- Resting heart rate (physical exam or 12 lead ECG) <60 bpm
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AAA617
Participants will receive a dose of 7.4 GBq (200 mCi) +/- 10% of AAA617 which will be administered once every 6 weeks (1 cycle) for 3 to 6 cycles according to eGFR calculation at screening and radiation absorbed dose results from Cycle1 Day1.
|
Administered intravenously once every cycles (1 cycle = 6 weeks)
Other Names:
Single intravenous dose of approximately 150 MBq
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absorbed radiation dose in kidneys and selected organs
Time Frame: Up to 36 weeks
|
The absorbed dose in kidneys and selected organs will be summarized with descriptive statistics.
|
Up to 36 weeks
|
Concentrations of AAA617 in blood over time
Time Frame: Cycle (C) 1 Day (D) 1 (pre dose, end of infusion, 20 minutes (min), 60 min, 2 and 4 hours (h) post infusion), C1 D2 (24 h post infusion), C1 D3 (48 h post infusion), C1 D4 (72 h post infusion), C1 D6 (156-168 h post infusion). Cycle=6 weeks
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.
Blood concentration of [177Lu]Lu-PSMA-617 will be summarized with descriptive statistics.
|
Cycle (C) 1 Day (D) 1 (pre dose, end of infusion, 20 minutes (min), 60 min, 2 and 4 hours (h) post infusion), C1 D2 (24 h post infusion), C1 D3 (48 h post infusion), C1 D4 (72 h post infusion), C1 D6 (156-168 h post infusion). Cycle=6 weeks
|
Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of 177Lu-PSMA-617
Time Frame: Cycle (C) 1 Day (D) 1 (pre dose, end of infusion, 20 minutes (min), 60 min, 2 and 4 hours (h) post infusion), C1 D2 (24 h post infusion), C1 D3 (48 h post infusion), C1 D4 (72 h post infusion), C1 D6 (156-168 h post infusion). Cycle=6 weeks
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.
AUClast will be listed and summarized using descriptive statistics.
|
Cycle (C) 1 Day (D) 1 (pre dose, end of infusion, 20 minutes (min), 60 min, 2 and 4 hours (h) post infusion), C1 D2 (24 h post infusion), C1 D3 (48 h post infusion), C1 D4 (72 h post infusion), C1 D6 (156-168 h post infusion). Cycle=6 weeks
|
Time of maximum observed drug concentration occurrence (Tmax) of 177Lu-PSMA-617
Time Frame: Cycle (C) 1 Day (D) 1 (2 and 4 hours (h) post infusion), C1 D2 (24 h post infusion), C1 D3 (48 h post infusion), C1 D4 (72 h post infusion), C1 D6 (156-168 h post infusion). Cycle = 6 weeks
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.
Tmax will be listed and summarized using descriptive statistics.
|
Cycle (C) 1 Day (D) 1 (2 and 4 hours (h) post infusion), C1 D2 (24 h post infusion), C1 D3 (48 h post infusion), C1 D4 (72 h post infusion), C1 D6 (156-168 h post infusion). Cycle = 6 weeks
|
Observed maximum plasma concentration (Cmax) of 177Lu-PSMA-617
Time Frame: Cycle (C) 1 Day (D) 1 (pre dose, end of infusion, 20 minutes (min), 60 min, 2 and 4 hours (h) post infusion), C1 D2 (24 h post infusion), C1 D3 (48 h post infusion), C1 D4 (72 h post infusion), C1 D6 (156-168 h post infusion). Cycle=6 weeks
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.
Cmax will be listed and summarized using descriptive statistics.
|
Cycle (C) 1 Day (D) 1 (pre dose, end of infusion, 20 minutes (min), 60 min, 2 and 4 hours (h) post infusion), C1 D2 (24 h post infusion), C1 D3 (48 h post infusion), C1 D4 (72 h post infusion), C1 D6 (156-168 h post infusion). Cycle=6 weeks
|
Terminal elimination half-life (T^1/2) of 177Lu-PSMA-617
Time Frame: Cycle (C) 1 Day (D) 1 (pre dose, end of infusion, 20 minutes (min), 60 min, 2 and 4 hours (h) post infusion), C1 D2 (24 h post infusion), C1 D3 (48 h post infusion), C1 D4 (72 h post infusion), C1 D6 (156-168 h post infusion). Cycle=6 weeks
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.
The half-live will be listed and summarized using descriptive statistics
|
Cycle (C) 1 Day (D) 1 (pre dose, end of infusion, 20 minutes (min), 60 min, 2 and 4 hours (h) post infusion), C1 D2 (24 h post infusion), C1 D3 (48 h post infusion), C1 D4 (72 h post infusion), C1 D6 (156-168 h post infusion). Cycle=6 weeks
|
Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) of 177Lu-PSMA-617
Time Frame: Cycle (C) 1 Day (D) 1 (pre dose, end of infusion, 20 minutes (min), 60 min, 2 and 4 hours (h) post infusion), C1 D2 (24 h post infusion), C1 D3 (48 h post infusion), C1 D4 (72 h post infusion), C1 D6 (156-168 h post infusion). Cycle=6 weeks
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.
AUC(0-inf) will be listed and summarized using descriptive statistics.
|
Cycle (C) 1 Day (D) 1 (pre dose, end of infusion, 20 minutes (min), 60 min, 2 and 4 hours (h) post infusion), C1 D2 (24 h post infusion), C1 D3 (48 h post infusion), C1 D4 (72 h post infusion), C1 D6 (156-168 h post infusion). Cycle=6 weeks
|
Total systemic clearance for intravenous administration (CL) of 177Lu-PSMA-617
Time Frame: Cycle (C) 1 Day (D) 1 (pre dose, end of infusion, 20 minutes (min), 60 min, 2 and 4 hours (h) post infusion), C1 D2 (24 h post infusion), C1 D3 (48 h post infusion), C1 D4 (72 h post infusion), C1 D6 (156-168 h post infusion). Cycle=6 weeks
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.
CL will be listed and summarized using descriptive statistics.
|
Cycle (C) 1 Day (D) 1 (pre dose, end of infusion, 20 minutes (min), 60 min, 2 and 4 hours (h) post infusion), C1 D2 (24 h post infusion), C1 D3 (48 h post infusion), C1 D4 (72 h post infusion), C1 D6 (156-168 h post infusion). Cycle=6 weeks
|
Volume of distribution during the terminal phase following intravenous elimination (Vz) of 177Lu-PSMA-617
Time Frame: Cycle (C) 1 Day (D) 1 (pre dose, end of infusion, 20 minutes (min), 60 min, 2 and 4 hours (h) post infusion), C1 D2 (24 h post infusion), C1 D3 (48 h post infusion), C1 D4 (72 h post infusion), C1 D6 (156-168 h post infusion). Cycle=6 weeks
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.
Vz will be listed and summarized using descriptive statistics.
|
Cycle (C) 1 Day (D) 1 (pre dose, end of infusion, 20 minutes (min), 60 min, 2 and 4 hours (h) post infusion), C1 D2 (24 h post infusion), C1 D3 (48 h post infusion), C1 D4 (72 h post infusion), C1 D6 (156-168 h post infusion). Cycle=6 weeks
|
Renal clearance of 177Lu-PSMA-617
Time Frame: Cycle 1 Day 1: end of infusion to 2 hours, 2 hours to 4 hours, 4 hours to 24 hours, 24 hours to 48 hours, 48 hours to 72 hours post infusion. Cycle = 6 weeks
|
The volume of each urine collection will be measured and the radioactivity concentration (KBq/mL) determined in order to calculate the total radioactivity excreted from the body from the start of infusion until 72h.
|
Cycle 1 Day 1: end of infusion to 2 hours, 2 hours to 4 hours, 4 hours to 24 hours, 24 hours to 48 hours, 48 hours to 72 hours post infusion. Cycle = 6 weeks
|
Change from baseline in eGFR
Time Frame: at screening and at every visit, assessed up to 1 year after last treatment
|
at screening and at every visit, assessed up to 1 year after last treatment
|
|
Dose modifications for AAA617
Time Frame: Up to 36 weeks
|
Dose modifications (dose interruptions and reductions) for AAA617 will be assessed and summarized using descriptive statistics.
|
Up to 36 weeks
|
Dose intensity for AAA617
Time Frame: Up to 36 weeks
|
Dose intensity for AAA617 will be assessed and summarized using descriptive statistics.
|
Up to 36 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in QTcF interval (ΔQTcF)
Time Frame: During Cycle 1 at predose, End of Injection (EoI), 20 minutes (min), 60 min, 2 hours (h), 4h and 24h post EoI. Cycle=6 weeks
|
During Cycle 1 at predose, End of Injection (EoI), 20 minutes (min), 60 min, 2 hours (h), 4h and 24h post EoI. Cycle=6 weeks
|
|
Relationship between drug concentrations and QTcF
Time Frame: During Cycle 1 at predose, End of Injection (EoI), 20 minutes (min), 60 min, 2 hours (h), 4h and 24h post EoI. Cycle=6 weeks
|
The relationship between 177Lu-PSMA-617 plasma concentrations and ΔQTcF will be investigated using a linear mixed-effects modeling approach with ΔQTcF as the dependent variable, time-matched 177Lu-PSMA-617 plasma concentration as the explanatory variable, centered baseline QTcF (i.e., baseline QTcF for individual patient minus the population mean baseline QTcF for all patients) as an additional covariate, a fixed intercept, and a random intercept and slope per patient, when applicable (Garnett et al1).
|
During Cycle 1 at predose, End of Injection (EoI), 20 minutes (min), 60 min, 2 hours (h), 4h and 24h post EoI. Cycle=6 weeks
|
Overall Response Rate (ORR)
Time Frame: From the date of 1st dose until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to approximately 36 weeks
|
Objective response rate (ORR) (CR + PR) as measured by PCWG3-modified RECIST v1.1 response in soft tissue, lymph node and visceral lesions as per local review and according to PCWG3-modified RECIST v1.1.
CR and PR must be confirmed by repeat assessments that should be performed not less than 4 weeks after the criteria for response are first met.
|
From the date of 1st dose until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to approximately 36 weeks
|
Disease Control Rate (DCR)
Time Frame: From the date of 1st dose until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to approximately 36 weeks
|
Disease Control Rate (DCR) (CR + PR + stable disease [SD]) as measured by PCWG3-modified RECIST v1.1 response in soft tissue, lymph node and visceral lesions.
DCR will be analyzed using the same analytical conventions as ORR.
|
From the date of 1st dose until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to approximately 36 weeks
|
PSA50 response
Time Frame: From screening up to 1 year
|
PSA50 response is defined as the proportion of participants who have a >= 50% decrease in PSA from baseline that is confirmed by a second (the next) PSA measurement >= 4 weeks later
|
From screening up to 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- mCRPC
- PSMA
- Renal impairment
- Dosimetry
- Prostate-specific membrane antigen
- QTc prolongation
- Metastatic Castration-Resistant Prostate Cancer
- Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
- Normal renal function
- lutetium (177Lu) vipivotide tetraxetan
- AAA617
- Moderately impaired renal function
- Severely impaired renal function
- post marketing requirement
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAAA617A12202
- 2023-503925-20-00 (Registry Identifier: EU CT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Castration-Resistant Prostate Cancer (mCRPC)
-
BayerCompletedMetastatic Castration-resistant Prostate Cancer (mCRPC)United States
-
FutureChemRecruitingMetastatic Castration-resistant Prostate Cancer, mCRPCKorea, Republic of
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
-
Constellation PharmaceuticalsActive, not recruitingMetastatic Castration Resistant Prostate Cancer (mCRPC)United States
-
Avionco LLCCompletedMetastatic Castration-Resistant Prostate Cancer (mCRPC)Russian Federation
-
UNC Lineberger Comprehensive Cancer CenterWithdrawnMetastatic Castration Resistant Prostate Cancer (mCRPC)United States
-
BayerCompletedMetastatic Castration Resistant Prostate Cancer (mCRPC)United States
-
Jiangsu HengRui Medicine Co., Ltd.CompletedMetastatic Castration-resistant Prostate Cancer (mCRPC)China
-
Memorial Sloan Kettering Cancer CenterProgenics Pharmaceuticals, Inc.CompletedProstate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)United States
-
PfizerCompletedMetastatic Castration Resistant Prostate Cancer (mCRPC) | Metastatic Castration Sensitive Prostate Cancer (mCSPC)Finland
Clinical Trials on AAA617
-
Novartis PharmaceuticalsRecruitingProstate CancerUnited States
-
Novartis PharmaceuticalsRecruitingOligometastatic Prostate Cancer (OMPC)Canada, Israel, Switzerland, Australia, Singapore
-
Novartis PharmaceuticalsRecruitingProstatic NeoplasmKorea, Republic of, Singapore, United States, Canada, Poland, Spain, Czechia
-
University College, LondonNovartis; Cancer Research UK; Janssen Pharmaceutica NVNot yet recruiting
-
Jonsson Comprehensive Cancer CenterNot yet recruitingProstate Carcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8United States
-
Mayo ClinicNot yet recruitingCastration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8United States
-
Jonsson Comprehensive Cancer CenterNovartis PharmaceuticalsNot yet recruitingCastration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8United States
-
University of WashingtonNovartis; Institute for Prostate Cancer Research (IPCR)Not yet recruitingCastration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate AdenocarcinomaUnited States